The dasatinib drugs market comprises drugs used for treating chronic myeloid leukemia (CML). Dasatinib is a potent inhibitor of Bcr-Abl and Src family kinases approved for the treatment of all phases of CML. It is effective as a first-line treatment and for patients who are resistant or intolerant to other tyrosine kinase inhibitors. Dasatinib drugs have minimal side effects and can halt the progression of CML at an early stage. The Global dasatinib drugs market is estimated to be valued at US$ 1350.6 Mn in 2024 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the dasatinib drugs market are Bristol-Myers Squibb Company, MSN Labs, Lupin, Dr. Reddy’s Laboratories, Gilead Sciences, Inc., Hetero Labs, MANUS AKTTEVA BIOPHARMA LLP, Alembic Pharma, JINLAN Pharm-Drugs Technology Co., Ltd., and Zhejiang Hisun Pharma. Bristol-Myers Squibb Company dominates the market with over 50% market share due to its pioneering drug Sprycel (dasatinib).
The key opportunities in the dasatinib drugs market include rising healthcare expenditure in emerging nations, increasing approvals for generic versions of dasatinib drugs offering cost-effective treatments. For example, in 2023 MSN Laboratories received USFDA approval for its generic dasatinib drug to treat CML.
On the global expansion front, key players are focusing on expanding their manufacturing facilities and distribution networks across Asian and Latin American countries. For instance, in 2021, Zhejiang Hisun Pharma inaugurated a new dasatinib API manufacturing plant in Haining City, China to cater to the growing demand from global markets.
Market drivers
Increasing prevalence of chronic myeloid leukemia globally is a major market driver. According to the World Health Organization, over 100,000 new cases of CML are reported annually worldwide. Growing geriatric population prone to develop CML will further drive market growth.
Market Restraints
Stringent regulations for the approval of generic versions of dasatinib drugs can hamper the growth of small players in the market. Secondly, the availability of alternative treatment options like imatinib also poses a challenge for dasatinib drugs market.
The report does not include any conclusion.
Segment Analysis
The dasatinib drugs market is dominated by the chronic myeloid leukemia sub segment. Over 70% of the dasatinib drugs sold are for the treatment of chronic myeloid leukemia. This is because dasatinib is one of the preferred treatment options for chronic phase chronic myeloid leukemia. It has high efficacy and is prescribed by doctors as the first line of treatment for chronic myeloid leukemia in many countries.
The other major sub segments include acute lymphoblastic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. These account for around 20-25% of the overall dasatinib drugs market. These indications see stable demand for dasatinib drugs due to availability of limited alternate treatment options and proven efficacy of dasatinib in these cancer types.
Global Analysis
North America dominates the global dasatinib drugs market with a share of over 40%. Wide acceptance of targeted cancer therapies and high diagnosis and treatment rates for chronic myeloid leukemia in the US and Canada drives the North America dasatinib drugs market. Europe is the second largest dasatinib drugs market led by countries like Germany, France and UK. Asia Pacific is the fastest growing region for dasatinib drugs market with nations like China, India and Japan having high prevalence of chronic myeloid leukemia and increasing healthcare spending on cancer treatment.
No comments:
Post a Comment